CO2021008245A2 - Food product with immunomodulatory effect - Google Patents
Food product with immunomodulatory effectInfo
- Publication number
- CO2021008245A2 CO2021008245A2 CONC2021/0008245A CO2021008245A CO2021008245A2 CO 2021008245 A2 CO2021008245 A2 CO 2021008245A2 CO 2021008245 A CO2021008245 A CO 2021008245A CO 2021008245 A2 CO2021008245 A2 CO 2021008245A2
- Authority
- CO
- Colombia
- Prior art keywords
- weight
- oil
- composition
- lactobacillus
- formulation
- Prior art date
Links
- 235000013305 food Nutrition 0.000 title abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 abstract 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- 235000019486 Sunflower oil Nutrition 0.000 abstract 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract 2
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 abstract 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 abstract 2
- 229950011318 cannabidiol Drugs 0.000 abstract 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 abstract 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000002600 sunflower oil Substances 0.000 abstract 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 abstract 1
- 241000193830 Bacillus <bacterium> Species 0.000 abstract 1
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 108010076119 Caseins Proteins 0.000 abstract 1
- 102000011632 Caseins Human genes 0.000 abstract 1
- 241000711573 Coronaviridae Species 0.000 abstract 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 abstract 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 240000001046 Lactobacillus acidophilus Species 0.000 abstract 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 abstract 1
- 240000006024 Lactobacillus plantarum Species 0.000 abstract 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 abstract 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 abstract 1
- 102000010445 Lactoferrin Human genes 0.000 abstract 1
- 108010063045 Lactoferrin Proteins 0.000 abstract 1
- 229920002774 Maltodextrin Polymers 0.000 abstract 1
- 239000005913 Maltodextrin Substances 0.000 abstract 1
- 229920000881 Modified starch Polymers 0.000 abstract 1
- 239000004368 Modified starch Substances 0.000 abstract 1
- 229920001100 Polydextrose Polymers 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 abstract 1
- 108010033929 calcium caseinate Proteins 0.000 abstract 1
- 235000010418 carrageenan Nutrition 0.000 abstract 1
- 239000000679 carrageenan Substances 0.000 abstract 1
- 229920001525 carrageenan Polymers 0.000 abstract 1
- 229940113118 carrageenan Drugs 0.000 abstract 1
- 239000002285 corn oil Substances 0.000 abstract 1
- 235000005687 corn oil Nutrition 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 abstract 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 abstract 1
- 235000019797 dipotassium phosphate Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 235000021323 fish oil Nutrition 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 abstract 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 abstract 1
- 229940072205 lactobacillus plantarum Drugs 0.000 abstract 1
- 229940078795 lactoferrin Drugs 0.000 abstract 1
- 235000021242 lactoferrin Nutrition 0.000 abstract 1
- 239000000944 linseed oil Substances 0.000 abstract 1
- 235000021388 linseed oil Nutrition 0.000 abstract 1
- 229940035034 maltodextrin Drugs 0.000 abstract 1
- 235000019426 modified starch Nutrition 0.000 abstract 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 235000013856 polydextrose Nutrition 0.000 abstract 1
- 239000001259 polydextrose Substances 0.000 abstract 1
- 229940035035 polydextrose Drugs 0.000 abstract 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000006041 probiotic Substances 0.000 abstract 1
- 235000018291 probiotics Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 229940080237 sodium caseinate Drugs 0.000 abstract 1
- 239000008347 soybean phospholipid Substances 0.000 abstract 1
- 239000004408 titanium dioxide Substances 0.000 abstract 1
- 229930003799 tocopherol Natural products 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- 235000019149 tocopherols Nutrition 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención hace referencia a una composición o formulación o suplemento dietario para la industria alimenticia y farmacológica para la prevención y tratamiento de enfermedades asociadas con inmunodeficiencias e infecciones virales causadas por virus tales como coronavirus SARS-Cov-2 (Covid-19) en donde los componentes de la composición o formulación o producto de acuerdo con la presente invención, son lactoferrina entre 3.00% y 4.00% en peso de la composición total, cannabidiol (CBD) en una proporción de 0.05% a 1.00% en peso de la composición total, aceite de girasol alto oleico entre 12.00% en peso, aceite de maíz entre un 8.00% y 9.00% en peso, aceite de girasol entre un 5.00% y 6.11% en peso, aceite de linaza entre un 3.00% y 4.00% en peso, aceite de pescado entre un 0.20% y 0.30%, fructooligosacáridos -FOS entre un 16.00% y 17.00% en peso, caseinato de calcio entre un 15.00% y 16.00% en peso, caseinato de sodio entre un 1.97% y 2.50% en peso, maltodextrina entre un 15.00% y 16.00% en peso, almidón modificado entre un 12.00% y 13.00% en peso; lecitina de soya entre un 0.40 y 0.60% en peso; dextrosa entre un 0.50% y 1.00% en peso, polidextrosa entre un 1.00% y 1.50% en peso, monoglicéridos destilados entre 0.50% y 1.00% en peso, fosfato dipotásico entre 0.50% y 0.70% en peso; dióxido de silicio entre 0.30% y 0.40% en peso, dióxido de titanio entre 0.020% y 0.022% en peso, tocoferoles (gamma, delta, alfa y beta) entre 0.090% y 0.150% en peso, ácido ascórbico entre 0.090% y 0.150% en peso, carragenano entre un 0.050% y 0.070% en peso, éster de ácido de monodiglicérido diacetil tartárico entre 0.040% y 0.060% en peso y probióticos (Lactobacillus acidophilus, Lactobacillus rhamnosu, Lactobacillus plantarum, Bifidobacterium lactis, Bacillus Coagulans) entre un 0.050 y 0.090% en peso.The present invention refers to a composition or formulation or dietary supplement for the food and pharmacological industry for the prevention and treatment of diseases associated with immunodeficiencies and viral infections caused by viruses such as coronavirus SARS-Cov-2 (Covid-19) where the components of the composition or formulation or product according to the present invention are lactoferrin between 3.00% and 4.00% by weight of the total composition, cannabidiol (CBD) in a proportion of 0.05% to 1.00% by weight of the total composition , high oleic sunflower oil between 12.00% by weight, corn oil between 8.00% and 9.00% by weight, sunflower oil between 5.00% and 6.11% by weight, linseed oil between 3.00% and 4.00% by weight , fish oil between 0.20% and 0.30%, fructooligosaccharides -FOS between 16.00% and 17.00% by weight, calcium caseinate between 15.00% and 16.00% by weight, sodium caseinate between 1.97% and 2.50% by weight , maltodextrin between a 15.0 0% and 16.00% by weight, modified starch between 12.00% and 13.00% by weight; soy lecithin between 0.40 and 0.60% by weight; dextrose between 0.50% and 1.00% by weight, polydextrose between 1.00% and 1.50% by weight, distilled monoglycerides between 0.50% and 1.00% by weight, dipotassium phosphate between 0.50% and 0.70% by weight; silicon dioxide between 0.30% and 0.40% by weight, titanium dioxide between 0.020% and 0.022% by weight, tocopherols (gamma, delta, alpha and beta) between 0.090% and 0.150% by weight, ascorbic acid between 0.090% and 0.150 % by weight, carrageenan between 0.050% and 0.070% by weight, diacetyl tartaric monodiglyceride acid ester between 0.040% and 0.060% by weight and probiotics (Lactobacillus acidophilus, Lactobacillus rhamnosu, Lactobacillus plantarum, Bifidobacillus lactis, Bacillus cousins) 0.050 and 0.090% by weight.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2020/056982 WO2021074706A1 (en) | 2020-07-24 | 2020-07-24 | Food product with immunomodulator effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021008245A2 true CO2021008245A2 (en) | 2021-07-09 |
Family
ID=75538407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0008245A CO2021008245A2 (en) | 2020-07-24 | 2021-06-24 | Food product with immunomodulatory effect |
Country Status (2)
| Country | Link |
|---|---|
| CO (1) | CO2021008245A2 (en) |
| WO (1) | WO2021074706A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100015791A1 (en) * | 2021-06-16 | 2022-12-16 | Aqma Italia S P A | COMPOSITION WITH IMMUNOSTIMULATING AND IMMUNO REGULATORY ACTIVITY TO PROMOTE THE IMMUNE RESPONSE OF THE HUMAN ORGANISM |
| WO2023044135A1 (en) * | 2021-09-17 | 2023-03-23 | 1242753 Ontario Inc. | Psilocybin derived compositions and methods of using same |
| IT202200023289A1 (en) | 2022-11-11 | 2024-05-11 | Global Pharmacies Partner S R L In Forma Abbreviata G P P S R L | NUTRACEUTIC SUPPLEMENT FOR THE PREVENTION AND TREATMENT OF RESPIRATORY TRACT INFECTIONS |
| WO2024144735A1 (en) * | 2022-12-28 | 2024-07-04 | Chivalric Regulus Biyoteknoloji Anonim Sirketi | A microencapsulated food supplement with probiotic microorganisms |
| WO2025045720A1 (en) * | 2023-08-25 | 2025-03-06 | Chr. Hansen A/S | Process for manufacturing a powder blend of oligosaccharides |
| CN117562937A (en) * | 2023-11-10 | 2024-02-20 | 哈尔滨天齐人类第二基因组技术开发应用科技有限责任公司 | Application of defatted flaxseed powder in the preparation of drugs against new coronavirus infectious diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009102677A1 (en) * | 2008-02-11 | 2009-08-20 | Tabatchnick Fine Foods, Inc. | A nutritionally enhanced therapeutic preventative food supplement and method of making same |
| CN102090558A (en) * | 2010-12-09 | 2011-06-15 | 上海交大昂立股份有限公司 | Composition containing probiotics, DHA (docosahexaenoic acid) and lactoferrin and applications thereof |
| US20120171164A1 (en) * | 2010-12-29 | 2012-07-05 | Anja Wittke | Use of nutritional compositions including lactoferrin in supporting resistance to viral respiratory tract infections |
| MX2013003636A (en) * | 2013-03-27 | 2014-09-29 | Palsgaard Ind De Mexico S De R L De C V | Food supplement for people with down syndrome, autism spectrum disorder and/or attention deficit disorder with or without hyperactivity. |
| US20170188616A1 (en) * | 2015-12-17 | 2017-07-06 | Therabis, Llc | Cannabinoid-enriched supplement |
-
2020
- 2020-07-24 WO PCT/IB2020/056982 patent/WO2021074706A1/en not_active Ceased
-
2021
- 2021-06-24 CO CONC2021/0008245A patent/CO2021008245A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021074706A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021008245A2 (en) | Food product with immunomodulatory effect | |
| Lara-Villoslada et al. | Beneficial effects of probiotic bacteria isolated from breast milk | |
| Patel | Functional food relevance of whey protein: A review of recent findings and scopes ahead | |
| Caballero-Franco et al. | The VSL# 3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells | |
| PE20110933A1 (en) | CHILDREN'S PROBIOTIC PRODUCTS | |
| PE20110932A1 (en) | CHILDREN'S PROBIOTIC PRODUCTS | |
| US20230381252A1 (en) | Dietary supplement | |
| Maftei | Probiotic, Prebiotic and Synbiotic | |
| Jonganurakkun et al. | Pediococcus pentosaceus NB-17 for probiotic use | |
| CN1694954B (en) | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter | |
| RU2011150214A (en) | Bifidobacterium longum NCC2705 (CNCM 1-2618) AND IMMUNE DISORDERS | |
| AR076862A1 (en) | NON-REPLICATING MICROORGANISMS AND ITS IMMUNOLOGICAL REINFORCEMENT EFFECT. COMPOSITION. METHOD FOR INCREASING EFFECTIVENESS OF PROBIOTICS | |
| Liang et al. | Progress of research and application of Heyndrickxia coagulans (Bacillus coagulans) as probiotic bacteria | |
| MY197201A (en) | Novel probiotics bifidobacteria strains | |
| Lokhande et al. | A systematic study of probiotics-an update review | |
| ZA202404359B (en) | Bacillus coagulans strain, compositions thereof, and methods of use | |
| US10933105B2 (en) | Composition for use as a support therapy for treatment of tumours, AIDS and leukaemia | |
| Wulandari et al. | Immunomodulatory and macrophage activating activity of Lactobacillus fermentum DLBSA204 in response to respiratory infection in a cellular model | |
| Foo et al. | Promising prospects of probiotics and postbiotics derived from lactic acid bacteria as pharma foods | |
| Lin et al. | Multi-strain probiotics combined with fruit-vegetable powders for regulating intestinal inflammation and intestinal epithelial barrier | |
| RU2003136785A (en) | THERAPEUTIC AND PREVENTIVE BIOLOGICAL PRODUCT BASED ON DRY BIOMASS BIFIDO- AND LACTOBACTERIA, BIOLOGICALLY ACTIVE ADDITIVE ON FOOD ON THE BASIS OF DRY BIOMASS BIBIDOFIT AND LIEF | |
| Cosentino | Functional foods and health: probiotics in health promotion and prevention | |
| Sheetal et al. | A New Therapeutic Approach Utilizes Probiotics, Prebiotics, Synbiotics, Postbiotics, and Gut Microbiota | |
| Zawistowska-Rojek et al. | How to Improve Health with Biological Agents—Narrative Review. Nutrients 2022, 14, 1700 | |
| Benomar et al. | Probiotics: Ways of Action and Beneficial Effects |